Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Diabetes Type 1 and Fitness. (Diab1Fit)

7 juli 2021 uppdaterad av: Poznan University of Medical Sciences

Assessment of Physical Effort in People With Newly Diagnosed Type 1 Diabetes Mellitus and Its Impact on: Partial Clinical Remission, Insulin Resistance, HDL Cholesterol Function, Immune Function and Length of Life.

The Diab1Fit Study project aims to a multidirectional assessment of physical activity and its impact in people with type 1 diabetes (DM1). To the study are recruited people with newly diagnosed DM1, treated with intensive functional insulin therapy from the beginning of the disease. The study is planned to cover a minimum of 100 people with newly diagnosed DM1 and lead prospective observation of this group (for a minimum of 5-10 years). The investigators will evaluate the effect of VO2max in people with newly diagnosed DM1 on partial clinical remission. What is more the investigators also assess quantitative and qualitative changes of plasma lipoproteins, with particular emphasis on HDL metabolism, mechanism linking VO2max with management of DM1 (longevity proteins, miostatin, insulin resistance) and immune function.

Studieöversikt

Status

Rekrytering

Betingelser

Detaljerad beskrivning

The Diab1Fit Study project aims to a multidirectional assessment of physical activity and its impact in people with type 1 diabetes (DM1). To the study are recruited people with newly diagnosed DM1, treated with intensive functional insulin therapy from the beginning of the disease. The study is planned to cover a minimum of 100 people with newly diagnosed DM1 and lead prospective observation of this group (for a minimum of 5-10 years). The investigators will evaluate the effect of VO2max in people with newly diagnosed DM1 on partial clinical remission. What is more the investigators also assess quantitative and qualitative changes of plasma lipoproteins, with particular emphasis on HDL metabolism, mechanism linking VO2max with management of DM1 (longevity proteins, miostatin, insulin resistance) and immune function.

Patients will be assessed: during the first hospitalization in the moment of diagnosis (prior to introduction of insulin treatment), after 3 weeks, after 6 months and after 12 months of insulin therapy. Further observations planned in the annual intervals. Further continuous observation with follow-up every year and evaluation of final end-points after 5 and 10 years. In addition, the study group will be under constant monitoring of metabolic evaluation every three months in the Outpatient Clinic. An additional visit to assess VO2max will be scheduled between 3 and 12 months of diabetes. The investigators will use an ergospirometer (COSMED K5 System) during an exercise test carried out on a cycloergometer (progressive exercise test). Moreover, the investigators will monitor glucose levels during the exercise test - using a continuous glucose monitoring system using the FreeStyle Libre Flash Glucose Monitoring System (Abbott). A week before the exercise test, the investigators will borrow a Garmin watch that assesses the patient's daily activities

During each follow-up will be assessed parameters:

  1. The presence of partial clinical remission, according to Mortensen: HbA1c (%) + [4 x dawka insuliny (j/kg/d)] ≤ 9.
  2. Data on lifestyle (diet, exercise), family history and smoking.
  3. Anthropometric data:

    1. BMI (body mass index) = weight [kg]/(height [m])2
    2. Waist circumference
    3. WHR - waist to hip ratio
    4. daily insulin requirement (U/kg m.c./d),
    5. eGDR (estimated glucose disposal rate) = 24.31-12.22(WHR)-3.29(hypertension 0/1)-0.57( HbA1c [mg/kg/min])
    6. VAI (visceral adiposity index):

      For women = [Waist circumference/36.58+(1.89xBMI)]x(TG/0.81)x(1.52/HDL), For men = [Waist circumference /39.68+(1.88xBMI)]x(TG/1.03)x(1.31/HDL),

    7. body composition analysis
  4. Parameters of diabetes metabolic control

    1. Lipid profile
    2. Glycated hemoglobin level (HbA1c)
  5. Protein glycation end products Expected impact of the research project on the development of science, civilization and society: The study confirms the great importance of aerobic physical activity in the treatment of people with DM1 from the beginning of the diagnosis. The project aims to pay attention to the importance of physical activity among people with DM1 and to popularize this method of treatment. The obtained results will be used for the prospective observation of this group to assess the impact of physical effort on the development of chronic complications and will allow planning intervention studies in this population. The results of this study will help enrich knowledge about the body's ability to exercise among people with DM1 and show new intervention solutions. It may contribute to changing the recommendations of scientific societies. What is more knowledge about prolonging partial clinical remission and thereby reducing the risk of developing chronic complications will contribute to the introduction of new recommendations. Research on exercise in diabetes and longevity proteins will increase the length and quality of life of people with DM1.

Studietyp

Observationell

Inskrivning (Förväntat)

100

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

      • Poznan, Polen, 60-834
        • Rekrytering
        • Department of Internal Medicine and Diabetiology Poznan University of Medical Sciences
        • Kontakt:
        • Kontakt:

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 35 år (Vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Testmetod

Icke-sannolikhetsprov

Studera befolkning

A minimum of 100 people with newly diagnosed type 1 diabetes hospitalized in the Department of Internal Medicine and Diabetology Poznan University of Medical Sciences.

Beskrivning

Inclusion Criteria:

  • Age 18-35 years,
  • New onset type 1 diabetes (confirmed by the presence of antibodies - antyGAD, ICA, IA2)
  • Treatment with intensive insulin therapy,
  • Written consent to participate in the study.

Exclusion Criteria:

  • Contraindications to the exercise test (including: recent myocardial infarction, unstable coronary artery disease, hypertrophic cardiomyopathy, serious arrhythmias, myocarditis, advanced systemic diseases, hyperthyroidism, recurrent anemia),
  • Mental disorders,
  • Co-morbidities with potential impact on physical performance (e.g. cancer, renal failure, liver failure, rheumatic diseases, COPD, asthma, anemia, hypothyroidism and hyperthyroidism),
  • Pregnancy.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Observationsmodeller: Endast fall
  • Tidsperspektiv: Blivande

Kohorter och interventioner

Grupp / Kohort
People with newly diagnosed diabetes mellitus type 1

People with newly diagnosed diabetes mellitus type 1 admitted to the Department of Internal Medicine and Diabetology.

Treated with intensive insulin therapy. Measurement of VO2max between 3 and 12 month after diagnosis. Further continuous observation with follow-up every year and evaluation of final end-points after 5 and 10 years.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
VO2max [ml/min/kg]
Tidsram: 1 year
VO2 max level evaluated during ergospirometry (COSMED K5)
1 year
Partial clinical remission time
Tidsram: 1 year
Presence [(4 x insulin dose (j/kg/d)] ≤ 9] and duration [time] of partial clinical remission
1 year

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Triglicerydes concentriation in serum [mg/dl]
Tidsram: Change from baseline in apolipoproteins' at 6 and 12 months
Changes in serum triglyceride levels
Change from baseline in apolipoproteins' at 6 and 12 months
LDL-C concentriation in serum [mg/dl]
Tidsram: Change from baseline in apolipoproteins' at 6 and 12 months
Changes in serum LDL levels
Change from baseline in apolipoproteins' at 6 and 12 months
HDL-C concentriation in serum [mg/dl]
Tidsram: Change from baseline in apolipoproteins' at 6 and 12 months
Changes in serum HDL levels
Change from baseline in apolipoproteins' at 6 and 12 months
Total Cholesterol concentriation in serum [mg/dl]
Tidsram: Change from baseline in apolipoproteins' at 6 and 12 months
Changes in serum Total-CH levels
Change from baseline in apolipoproteins' at 6 and 12 months
Lipid tissue content [%]
Tidsram: 5 years
Evaluation of lipid tissue content prior to yearly visit.
5 years
A1c [%]
Tidsram: 5 years
Changes in serum A1c levels
5 years
Daily insulin requirement [u/kg/d]
Tidsram: 1 year
Sum of insulin units administered in the day prior to yearly visit.
1 year
Retinopathy
Tidsram: 5 years
Evaluation of retinopathy (ophthalmology assessment)
5 years
Neuropathy
Tidsram: 5 years
Evaluation of presence of neuropathy peripheral and autonomic (clinical examination, Visual Analog Score for pain and ProsciCard)
5 years
eGFR [ml/min/1,73m2]
Tidsram: 5 years
Assessment of glomerular filtration and renal filtration function
5 years
Creatynine [mg/dl]
Tidsram: 5 years
Assessment of renal function
5 years
Albumine to creatynine ratio ACR [mg/g]
Tidsram: 5 years
Assessment of renal function
5 years

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

1 januari 2020

Primärt slutförande (Förväntat)

31 december 2022

Avslutad studie (Förväntat)

31 december 2025

Studieregistreringsdatum

Först inskickad

13 augusti 2020

Först inskickad som uppfyllde QC-kriterierna

7 juli 2021

Första postat (Faktisk)

20 juli 2021

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

20 juli 2021

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

7 juli 2021

Senast verifierad

1 juli 2021

Mer information

Termer relaterade till denna studie

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

produkt tillverkad i och exporterad från U.S.A.

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Kliniska prövningar på Diabetes mellitus

3
Prenumerera